Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acrivon Therapeutics, Inc. - Common Stock
(NQ:
ACRV
)
9.360
+0.670 (+7.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acrivon Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
January 03, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
Analyst Ratings for Acrivon Therapeutics
November 10, 2023
Via
Benzinga
Recap: Acrivon Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
November 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Analyst Expectations for Acrivon Therapeutics's Future
October 05, 2023
Via
Benzinga
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
September 19, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
September 05, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Participate in Two Investor Conferences in September
August 30, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2023
August 18, 2023
Via
Benzinga
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 11, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
July 20, 2023
Dr. Levy brings more than 25 years of biopharma industry experience, including at Zentalis Pharmaceuticals, Turning Point Therapeutics and Gilead Sciences
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
7 Up-and-Coming Stocks to Buy for the Next Decade
June 29, 2023
While less-established enterprises are best left for speculators, these up-and-coming stocks to buy also feature huge upside potential.
Via
InvestorPlace
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
June 22, 2023
Dr. Baum comes with more than 30 years of biopharma industry leadership experience, including at Mirati Therapeutics, Pfizer and Schering-Plough
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
June 02, 2023
Via
Benzinga
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
May 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
May 08, 2023
Via
Benzinga
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
April 24, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.